ID: ALA4288808

Max Phase: Preclinical

Molecular Formula: C21H26N2O4S

Molecular Weight: 402.52

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)(C)c1coc(S(=O)(=O)NC(=O)Nc2c3c(cc4c2CCC4)CCC3)c1

Standard InChI:  InChI=1S/C21H26N2O4S/c1-21(2,3)15-11-18(27-12-15)28(25,26)23-20(24)22-19-16-8-4-6-13(16)10-14-7-5-9-17(14)19/h10-12H,4-9H2,1-3H3,(H2,22,23,24)

Standard InChI Key:  JHURPJUJPGHVIU-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 402.52

Molecular Weight (Monoisotopic): 402.1613

AlogP: 4.06

#Rotatable Bonds: 3

Polar Surface Area: 88.41

Molecular Species: ACID

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 5.01

CX Basic pKa:

CX LogP: 5.27

CX LogD: 4.34

Aromatic Rings: 2

Heavy Atoms: 28

QED Weighted: 0.81

Np Likeness Score: -0.62

References

1. Fulp J, He L, Toldo S, Jiang Y, Boice A, Guo C, Li X, Rolfe A, Sun D, Abbate A, Wang XY, Zhang S..  (2018)  Structural Insights of Benzenesulfonamide Analogues as NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization.,  61  (12): [PMID:29877709] [10.1021/acs.jmedchem.8b00733]

2. Xu Y, Xu Y, Blevins H, Guo C, Biby S, Wang XY, Wang C, Zhang S..  (2022)  Development of sulfonamide-based NLRP3 inhibitors: Further modifications and optimization through structure-activity relationship studies.,  238  [PMID:35635948] [10.1016/j.ejmech.2022.114468]

Source

Source(1):

• Scientific Literature